BamSEC and AlphaSense Join Forces
Learn More

Kalaris Therapeutics Inc.

NASDAQ: KLRS    
Share price (3/25/25): $8.82    
Market cap (3/25/25): $165 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.8
from 8-K 73 pages Lease Between the Connell Company Landlord and Kalaris Therapeutics, Inc. Tenant 400 Connell Drive
12/34/56
EX-10.7
from 8-K 10 pages Kalaris Therapeutics, Inc. [Form Of] Officer Indemnification Agreement
12/34/56
EX-10.6
from 8-K 11 pages Kalaris Therapeutics, Inc. [Form Of] Director Indemnification Agreement
12/34/56
EX-10.5
from 8-K 42 pages Kalaris Therapeutics, Inc. 2020 Stock Option and Grant Plan, as Amended
12/34/56
EX-10.4
from 8-K 53 pages Napoco, Inc. 2019 Equity Incentive Plan as Adopted on September 30, 2019
12/34/56
EX-10.3
from 8-K 11 pages December 31, 2024 Matthew Feinsod, MD [***] [***] [***] [***] Re: Offer of Employment by Kalaris Therapeutics, Inc. Dear Matt: I Am Very Pleased to Confirm Our Offer to You of Employment With Kalaris Therapeutics, Inc. (The “Company”). the Terms of Our Offer and the Benefits Currently Provided by the Company Are as Follows
12/34/56
EX-10.31
from S-4/A 10 pages April 18, 2024 (As Revised at Your Request on April 26, 2024) Jeffrey Nau, Phd, Mms [***] Re: Offer of Employment by Theia Therapeutics, Inc. Dear Jeff: I Am Very Pleased to Confirm Our Offer to You of Employment With Theia Therapeutics, Inc. (The “Company”). the Terms of Our Offer and the Benefits Currently Provided by the Company Are as Follows
12/34/56
EX-10.30
from S-4/A 9 pages February 23, 2024 Andrew Oxtoby [***] Re: Offer of Employment by Theia Therapeutics, Inc. Dear Andrew: I Am Very Pleased to Confirm Our Offer to You of Employment With Theia Therapeutics, Inc. (The “Company”). the Terms of Our Offer and the Benefits Currently Provided by the Company Are as Follows
12/34/56
EX-10.1
from 8-K 6 pages Separation Agreement and Release
12/34/56
EX-10.6
from S-4 10 pages Consulting Agreement
12/34/56
EX-10.5
from S-4 8 pages Via Electronic Mail April 10, 2024 (As Revised on April 23, April 26, and April 29 at Your Request) Kourous Rezaei [***] Dear Kourous
12/34/56
EX-10.4
from S-4 6 pages Business Services Agreement
12/34/56
EX-10.3
from S-4 11 pages Royalty Agreement
12/34/56
EX-10.2
from S-4 29 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions. License Agreement Between Theia Therapeutics, Inc. and the Regents of the University of California for Case No. [**] [**] License Agreement
12/34/56
EX-10.1
from S-4 23 pages Napoco, Inc. 2019 Equity Incentive Plan as Adopted on September 30, 2019
12/34/56
EX-10.3
from 8-K 6 pages Form of Lock-Up Agreement
12/34/56
EX-10.2
from 8-K 9 pages Form of Company Stockholder Support Agreement
12/34/56
EX-10.1
from 8-K 9 pages Form of Parent Stockholder Support Agreement
12/34/56
EX-10.1
from 8-K 3 pages Termination Agreement
12/34/56
EX-10.1
from 8-K 8 pages Termination of Sublease Agreement
12/34/56